Abstract: The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.

Abstract: RGMb antagonists reduce undesirable immune responses associated with tissue or organ transplantation.

Abstract: The application provides methods of detection, diagnosis, prognosis, prophylaxis and treatment of folate receptor-alpha-expressing gastric cancer using antibodies that specifically bind to folate receptor alpha.

Abstract: The present application disclose a method for treating a patient who would benefit from stimulation of the patient's stem cells, comprising administering to the patient an antibody that specifically binds to an epitope of the MUC1 protein expressed on human undifferentiated stem cells.

Abstract: Methods for diagnosing and treating conditions associated with life-threatening neurological complications are provided. The methods involve in some aspects the identification of oxLDL and LOX-1 as critical players in pregnant subjects and in some cases subjects having severe preeclampsia (early onset preeclampsia). Related products and kits are also provided.

Abstract: Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).

Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: Compositions and methods that utilize anti-CD11b antibodies, anti-CD18 antibodies, anti-myeloperoxidase (MPO) antibodies, anti-integrin ?V antibodies, anti-integrin ?1 antibodies, Abciximab, neutrophil inhibitory factor (NIF) protein, and/or combinations thereof to treat solid tumor cancers are described.

Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.

Abstract: The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations.

Abstract: The present disclosure relates to conjugates comprising biologically active molecules linked to a multimeric antigen-binding compound or a multimeric immunoglobulin via a linker. The disclosure further provides reagents and methods of manufacturing the conjugates and the linkers. The disclosure also provides compositions comprising the conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.

Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.

Abstract: There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.

Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.

Abstract: The invention relates to the use of a binding member that binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody that binds to SCR1 and SCR2 of CD55 and neutralizing CD55 and making cancer cells susceptible to complement-mediated attack.

Abstract: Anti-human chemokine (C—C motif) Receptor 4 immunotoxins and methods of use thereof, e.g., for depleting Tregs as an immunotherapy for the treatment of cancer; for the treatment of cancers associated with CCR4+ tumor cells such as skin homing cutaneous T cell lymphoma, adult T cell leukemia/lymphoma, and acute T-cell lymphoblastic leukemia; and for the depletion of CCCR4+ Th2 cells for the treatment of allergy-related conditions such as asthma.

Abstract: Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multispecific antibodies against IL1RAP and CD3 described herein.

Abstract: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

Abstract: The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.

Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.

Abstract: A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

Abstract: Antibodies are raised against compounds of Formula (I) where Z is an immunogenic carrier. These compounds are capable of binding specifically to corresponding antibodies. The antibodies are specific for epimers of vitamin D. Antibodies in accordance with the principles described herein may be employed to minimize or eliminate 3-epimer cross-reactivity in assays for non-epimeric forms of vitamin D analytes. Over-estimation of total non-epimeric vitamin D analyte caused by the cross-reactivity of 3-epimer vitamin D with an antibody for vitamin D analyte can be substantially avoided employing, as blocking agents, antibodies prepared against immunogens that are a compound of the Formula (I) wherein Z is an immunogenic carrier.

Abstract: A method is provided for the post-treatment of nanoporous celluloses with an eye to scale up to plant operation wherein recycling and recovery of reagents is crucial in the efficient and cost effective operation of a full-scale plant. The instant method includes diminishing the alkali (e.g., sodium hydroxide) concentration of the treatment solution by converting it to a salt (e.g., a sodium salt).

Abstract: The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as glucuronoxylan sulfate (GXS). The invention has been developed primarily for use in the treatment of various clinical conditions. However, it will be appreciated that the invention is not restricted this particular field of use.

Abstract: Provided is a modified rubber for a tire (A) obtained by modifying a natural rubber and/or a synthetic rubber with a compound represented by formula (1): wherein X is an acid to form a salt with a guanidine site.

Abstract: The present disclosure relates to a Ziegler-Natta catalyst composition comprising: i. at least one pro-catalyst comprising: a morphologically modified magnesium alkoxide as a support; at least one titanium halide; at least one first internal donor and at least one second internal donor; and at least one inert hydrocarbon medium, ii. at least one organo-aluminum compound as a co-catalyst; and iii. at least one external donor comprising an organo-silane compound and a carboxylic acid ester. The present disclosure also relates to a process for the preparation of the Ziegler-Natta catalyst composition.

Abstract: Catalyst composition comprising a phthalate-free electron donor, which is highly effective during polymerisation in the presence of a polymeric nucleating agent, and its use and a process for its preparation.

Abstract: A propylene-based polymer resin is characterized by a low volatile emission signature. For example, the propylene-based polymer resin may have a volatile organic compound content no greater than 125 ppm, a semi-volatile organic compound content no greater than 500 ppm, and a C36 oligomeric content no greater than 250 ppm.

Abstract: The presently disclosed and claimed inventive concept(s) relates to solid catalyst components comprising titanium, magnesium, halogen and an internal electron donor compound having at least one ester group and at least one alkoxy group, and catalyst systems containing the catalyst solid components, organoaluminum compounds, and organosilicon compounds. The presently disclosed and claimed inventive concept(s) further relates to methods of making the catalyst components and the catalyst systems, and methods of polymerizing or copolymerizing alpha-olefins using the catalyst systems.

Abstract: The invention relates to a process a system and a high pressure pump for the preparation of a copolymer of ethylene and a di- or higher functional (meth) acrylate in a tubular reactor, comprising the steps of: injecting ethylene at a pressure of 100 MPa to 350 MPa into the reactor from a high pressure compressor and injecting the (meth)acrylate at a pressure of 100 MPa to 350 MPa into the reactor from a high pressure pump, wherein the high pressure pump comprises—a pump suction chamber for receiving a medium to be compressed; —a cylinder for receiving the medium to be compressed from the pump suction chamber; —an outlet for discharging a compressed medium from the cylinder, —a seal fixed to the inner wall of the cylinder at an end of the cylinder distal to the outlet and —a plunger movable in the cylinder by sliding through the seal, wherein a leakage gap is present along the plunger and the leakage gap is fluidly connected to the pump suction chamber.

Abstract: A copolymer has high levels of multolefin incorporation. A process for producing the copolymer having high levels of multiolefin incorporation involves contacting at least one isoolefin monomer with at least one multiolefin and/or ?-pinene monomer in the presence of at least one Lewis acid and at least one initiator in a diluent. The diluent contains a hydrofluor-Mated olefin (HFO) comprising at least three carbon atoms and at least three fluorine atoms. Hydrofluorinated olefins used in the present invention are better diluents for butyl slurry cationic polymerization than saturated hydro-fluorocarbons.

Abstract: Disclosed are a heat-resistant SAN resin, a method of producing the same and a heat-resistant SAN resin composition comprising the same. More specifically, disclosed are a heat-resistant SAN resin produced using ingredients comprising 52 to 78% by weight of alpha-methylstyrene, 20 to 40% by weight of a vinyl cyanide compound and 2 to 8% by weight of hydroxyalkyl (meth)acrylate, a method of producing the same and a heat-resistant SAN resin composition comprising the same. Advantageously, provided are a heat-resistant SAN resin with maintained heat resistance, improved polymerization conversion rate and increased weight average molecular weight, a method of producing the same, and a heat-resistant SAN resin composition containing the same with excellent chemical resistance, superior mechanical properties and good balance between properties.

Abstract: A pattern forming method includes forming a film using an actinic ray-sensitive or radiation-sensitive resin composition, exposing the film with active light or radiation, and developing the exposed film using a developer including an organic solvent, in which the actinic ray-sensitive or radiation-sensitive resin composition contains a compound having a partial structure represented by General Formula (I).

Abstract: The present invention relates to a method for preparing a vinyl chloride copolymer having good heat resistance and a vinyl chloride copolymer produced by the same. In the preparation method, by not injecting an N-substituted maleimide based compound used as a comonomer together with a vinyl chloride monomer at one time in a pre-polymerization step, but in division in a specific ratio, a copolymer with a uniform distribution of the N-substituted maleimide based compound and the vinyl chloride monomer may be easily prepared, and the vinyl chloride copolymer may have good heat resistance. Accordingly, the preparation method of a vinyl chloride copolymer and the vinyl chloride copolymer according to the present invention may be easily applied to industries requiring the copolymer, particularly industries requiring a resin having good heat resistance as well as industries using a vinyl chloride resin.

Abstract: An acrylic rubber contains (a) methyl methacrylate units, (b) ethyl acrylate units, (c) n-butyl acrylate units, (d) 2-methoxyethyl acrylate units, and (e) cross-linking site monomer units, in which the acrylic rubber contains 10 to 20% by weight of (a) the methyl methacrylate units, 15% by weight or less of (b) the ethyl acrylate units, 60 to 80% by weight of (c) the n-butyl acrylate units, 10 to 30% by weight of (d) the 2-methoxyethyl acrylate units, and 0.5 to 5% by weight of (e) the cross-linking site monomer units.

Abstract: Random terpolymers are characterized for being tolerant to high concentrations of divalent ions, such as calcium, magnesium, strontium and barium, and that for their application in the reservoir or production rig, treated water, sea water and/or connate water can be used as means of transportation. Furthermore, the terpolymer also can be used to inhibit and disperse mineral scales presents in cooling system and boiler employed in the chemical and oil industry. Also, random terpolymers of the present invention have the characteristic of complying with environmental standards established internationally and are classified as particularly non-toxic, so it can be used in pipes and equipment of the petrochemical industry and with the use characteristic freshwater and seawater from offshore and onshore facilities.

Abstract: A polymer having a partial structure formed by performing radical polymerization with respect to a compound having a mesogenic group derived from at least one type of liquid crystal compound selected from a rod-like liquid crystal compound and a disk-like liquid crystal compound, and two or more polymerizable groups, in which the polymer is a branched polymer, and a composition containing the polymer, an optical film, and a liquid crystal display device.

Abstract: The present invention relates to a siliconized hybrid latex that consists of a polysiloxane methacrylic copolymer of the formula (I), starting with at least one methacrylic monomer that is partially soluble in water, and at least one functionalised silicone-based macromonomer that is insoluble in water and highly hydrophobic, and to the use of said latex in a water-based formula, free of fluorinated compounds, generating highly hydrophobic or superhydrophobic surfaces with self- or easy-cleaning properties.

Abstract: Compositions, methods, and resins using alkyl aldehydes and phenols are provided herein. In one embodiment, a composition comprising an alkylphenol resin can be prepared by condensing at least one phenolic monomer selected from the group consisting of phenol, cresol, resorcinol, xylenol, ethyl phenol, alkylresorcinols, and combinations thereof; and at least one alkyl aldehyde having from 5 to 12 carbon atom alkyl groups. The alkylphenol resins of the application are free of octylphenol or nonylphenol monomers. In one embodiment, the alkylphenol resins may be prepared using formaldehyde, and alternatively, in another embodiment, the alkylphenol resins may be prepared without the use of formaldehyde. The process to make these new alternative alkylphenol resins is a cost effective process and easy to scale-up.

Abstract: The present invention provides a novolac-type phenolic hydroxyl group-containing resin having as a repeating unit a structural site represented by structural formula (1) below [in the formula, R1 represents any one of a hydrogen atom, an alkyl group, and an aryl group, and X represents a structural site (?) represented by structural formula (2) below (in the formula, R2 and R3 each represent any one of a hydrogen atom, an alkyl group, an aryl group, and an aralkyl group; n and m are each an integer of 1 to 3; when n or m is 2 or 3, a plurality of each of R2 and R3 present in a molecule may be the same or different; and Ar represents any one of a phenyl group, a naphthyl group, an anthryl group, and a structural site)].

Abstract: Methods, compounds, and compositions described herein generally relate to polyalkylamines and syntheses thereof. In some embodiments, a chemical compound has the formula: Each instance of R is independently selected from the group consisting of aryl, alkyl, and polyether. Each instance of R? is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, polyether, and alcohol. Each instance of Q and Z is independently a covalent bond or selected from the group consisting of alkyl and aralkyl.

Abstract: A viscoelastic polyurethane foam formed from a polyisocyanate and a polyol composition comprising palm olein-based polyol in an amount of 10% to 35% by weight of the total polyol composition and petroleum-based polyol in an amount of 65% to 90% by weight of the total polyol composition. The dissipation energy of the viscoelastic polyurethane foam is between 0.01 J to 0.30 J as calculated based on a hysteresis loop normalized a density of 40.80 kg/m3. This shows that the viscoelastic foam produced has an improved dampening property. The introduction of palm olein-based polyol into the production of viscoelastic foam does not affect the support factors and mechanical properties of the foam produced. The viscoelastic foams can be produced using an amount of up to 35% of palm olein-based polyol derived from palm olein or up to 25% of palm olein-based polyol derived from a mixture of palm olein and soybean oil by weight of total composition without any adjustment in the catalyst package.

Abstract: The invention relates to polyisocyanates that have aliphatically, cycloaliphatically, araliphatically and/or aromatically bonded isocyanate groups and contain thioallophanate structures of formula (I), to a method for producing them, and to their use as starting components in the production of polyurethane plastics.

Abstract: The present invention provides a soft polyurethane foam that is obtained by foam molding a foaming stock solution containing a polyol, a polyisocyanate, a cross-linking agent, a foaming agent, and a catalyst in which: a polyether polyol having a weight-average molecular weight (Mw) of 3,000 to 12,000 and having three to four functional groups is contained; a molar ratio of ethylene oxide groups/propylene oxide groups in all the compound contained as the cross-linking agent is 100 or more; and diphenylmethane diisocyanate is contained in an isocyanate index of 70 or more.

Abstract: The invention relates to a composition for producing transparent polythiourethane bodies containing or consisting of A) a polyisocyanate component containing at least one polyisocyanate with a functionality of isocyanate groups of at least 2 per molecule, B) a thiol component containing at least one polythiol with a functionality of thiol groups of at least two per molecule, in addition to optionally C) auxiliary agents and additives, the ratio of isocyanate groups to groups reactive in relation to isocyanates being 0.5:1 to 2.0:1. The composition is characterised in that the polyisocyanate of the polyisocyanate component A) is produced by a gas-phase phosgenation of aliphatic, cycloaliphatic, aromatic or araliphatic polyamines.

Abstract: The invention relates to thioallophanates which contain silane groups and are of the general formula (I) in which R1, R2 and R3 are identical or different radicals and are each a saturated or unsaturated, linear or branched, aliphatic or cycloaliphatic radical or an optionally substituted aromatic or araliphatic radical having up to 18 carbon atoms, where said radical may optionally contain up to 3 heteroatoms from the group of oxygen, sulphur and nitrogen, X is a linear or branched organic radical having at least 2 carbon atoms, Y is a linear or branched, aliphatic or cycloaliphatic radical or an araliphatic or aromatic radical having up to 18 carbon atoms, and n is an integer from 1 to 20, to a process for preparation thereof, and to the use thereof as starting components in the production of polyurethane plastics.

Abstract: Provided is an epoxy resin which has a low viscosity and excellent impregnation capability into reinforcing fibers and provides a cured product having a high elastic modulus and excellent heat resistance when the epoxy resin is used for a fiber-reinforced resin material, and a method for producing the epoxy resin, a curable resin composition, and a cured product thereof, a fiber-reinforced composite material, and a molded article. An epoxy resin which is polyglycidyl ether that is a polycondensation product of phenol and hydroxybenzaldehyde, the resin includes the trinuclear body (X) represented by the following Structural Formula (1), in which the content of a [o,p,p] bonding body (x1) represented by the following Structural Formula (1-1) among the trinuclear body (X) is in the range of 5% to 18% in terms of an area ratio as measured by liquid chromatography.

Abstract: The invention is directed to a curable composition, which comprises an epoxy resin mixture, wherein the epoxy resin mixture comprises a) an epoxy resin; b) diethyl methyl benzene diamine (DETDA) as hardener; c) at least one compound selected from the group consisting of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) as catalyst.